Table 6 Impact of resveratrol on the expression of genes in the context of hematological malignancies

Leukemia

In vitro

10 mM

K562/ADR, K562

P-gp, Caspase-3/8, ERK1/2, JNK

PI3K/AKT/mTOR

RVT via suppressing the PI3K/AKT/mTOR pathway could increase the anti-proliferative activity of bestatin

[59]

Leukemia

In vitro

0–20 μM

PBMCs, HL-60, NB-4

–

PTEN/PI3K/AKT

RVT via regulating the PTEN/PI3K/AKT pathway could affect apoptosis and proliferation of leukemia cells

[60]

Acute Myeloid Leukemia (AML)

In vitro

25–200 lmol/L

HL-60, HL-60/ADR

MRP1

PI3K/AKT/Nrf2

RVT via the PI3K/AKT/Nrf2 Pathway could reverse the drug resistance of AML HL-60/ADR cells

[61]

Chronic Myeloid Leukemia (CML)

In vitro

60 μM

K562

p70S6K, 4EBP1, Cyclin-D1, Caspase-3,

PI3K/AKT/mTOR

RVT via downregulating the PI3K/AKT/mTOR pathway could play a role in the apoptosis of K562 cells

[62]